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Estrogen exerts complex biological effects through the two isoforms of estrogen receptors (ERs): ERα and
ERβ.Whether through alteration of gene expression or rapid, plasma membrane-localized signaling to
non-transcriptional actions, estrogen-activated ERs have significant implications in cardiovascular physiology.
17-β-estradiol (E2) generally has a protective property on the vasculature. Estrogen treatment is
anti-atherogenic, protecting injured endothelial surfaces and lowering LDL oxidation in animal models.
Increased NO production stimulated by E2 results in vasodilation of the coronary vascular bed, and involves
rapid activation of phosphotidylinositol-3 kinase (PI3K)/Akt signaling to eNOS in carotid and femoral arteries.
Both isoforms of ERs impact various vascular functions, modulating ion channel integrity, mitigating the
response to arterial injury, inducing vasodilation, and preventing development of hypertension in animal
models. In addition to reducing afterload by vasodilation, ERs have a direct antihypertrophic effect on the
myocardium. E2-activated ERs (E2/ER) antagonize the hypertrophic pathway induced by vasoactive peptides
such as angiotensin II by activating PI3K, subsequent MICIP gene expression, leading to the inhibition of
calcineurin activity and the induction of hypertrophic genes. In models of ischemia-reperfusion, E2/ER is
antiapoptotic for cardiomyocytes, exerting the protective actions via PI3K and p38 MAP kinases and
suppressing the generation of reactive oxygen species. In sum, E2-activated ERs consistently and positively
modulate multiple aspects of the cardiovascular system.
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Introduction
Estrogen exerts complex biological effects through its
cognate receptors.There are two isoforms of estrogen
receptors (ERs): ERα and ERβ, which are encoded by
distinct genes with different levels of expression in various
tissue types [Nilsson and Gustafsson, 2002]. Both are
found in endothelium of human blood vessels and in the
myocardium [Grohe et al., 1997; Karas et al., 1994;
Kim-Schulze et al., 1996]. As members of the nuclear
receptor superfamily, ERs positively regulate gene
expression by binding to target gene estrogen response
elements, modifying the binding of other transcription
factors, and recruiting co-activators to the
transcriptosome. ERs also participate in rapid, plasma
membrane-initiated steroid signaling (MISS), which in
part impacts transcription.Whether through alteration of
gene expression or through protein modification by rapid
signaling, estrogen-activated ERs significantly modulate
cardiovascular physiology.This article focuses on multiple
actions of estrogen and ligand-dependent ERs relevant
to the cardiovascular system.
Role of estrogen in vasculature
Estrogen has often been shown to prevent vascular
dysfunction and injury. 17-β-estradiol (E2) accelerates
endothelial recovery and increases nitric oxide (NO)
production after de-endothelializing balloon injury
[Krasinski et al., 1997].This is ER-dependent, as shown
in studies utilizing a specific ER inhibitor, ICI182780, and
is absent in ERα knockout (KO) mice [Bakir et al., 2000;
Karas et al., 2001]. Increased NO production induced by
E2 results in vasodilation of the coronary microvasculature
[Thompson et al., 2000], carotid and femoral arteries [Guo
et al., 2005]. Recent data derived from comparison of
wild type, ovariectomized, and eNOS-null mice show that
expression of endothelial nitric oxide synthase (eNOS)
is significantly reduced in ovariectomized mice.
Furthermore, eNOS is induced by E2 [Lantin-Hermoso
et al., 1997], and this interaction relieves stress and strain
on the arterial wall [Guo et al., 2006]. Rapid activation of
eNOS by E2 occurs in minutes, and suggests
non-transcriptional actions or MISS [Caulin-Glaser et al.,
1997; Chen et al., 1999]. E2-mediated eNOS activation
results from rapid activation of phosphotidylinositol-3
kinase (PI3K)/Akt, demonstrated in cultured human
endothelial cells (EC) [Haynes et al., 2000] as well as in
intact elastic and muscular arteries in vivo [Guo et al.,
2005; Haynes et al., 2000]. E2-mediated vasodilation is
also absent in eNOS KO mice, confirming the interaction
between E2/ER and eNOS in influencing the vascular
tone [Guo et al., 2005].
Direct binding of ERα to the p85 subunit of PI3K and
increased PI3K activity (resulting in activation of Akt and
eNOS) has been reported to occur in an E2-dependent
fashion, blocked by estrogen receptor antagonists
ICI182780 and tamoxifen [Simoncini et al., 2000]. In
addition, E2-dependent rapid activation of eNOS occurs
via an interaction between ERα and the Gαi-protein
[Wyckoff et al., 2001].
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as a G-protein-coupled receptor (GPCR)? The structure
of ERα is much different from that of classical GPCRs,
and endogenous ERα is unlikely to span the plasma
membrane of cells. However, collective evidence (e.g.
membrane localization, activation of signaling cascades,
association with G-proteins) implicates that ERα can
participate in MISS via G-protein activation to downstream
signaling [Kelly and Levin, 2001]. In some situations, this
could involve membrane ER or E2-activation of an orphan
GPCR, like GPR30 [Revankar et al., 2005], but this is
controversial.
Although ERα alone was sufficient to bind and activate
PI3K in the study by Simoncini et al., it does not preclude
a potential recruitment of ERβ to form heterodimers that
enact signaling. Chambliss and colleagues demonstrated
rapid signaling actions of ERβ at membrane-associated
caveolae [Chambliss et al., 2002]. Furthermore, work
from our own laboratory indicates that plasma membrane
ERs function as dimers to bind and activate G-protein
subunits.While most endogenous plasma membrane
ERs exist as homodimers in the presence of E2, a small
portion of the receptor pool forms ERα/ERβ heterodimers
[Razandi et al., 2004].We also reported that in vivo kinase
activation and arterial vasodilator responses to E2 are
absent in either ERα or ERβ KO mice, indicating that both
ER isoforms cooperate to impact vascular functions [Guo
et al., 2005].We believe that the in vitro data
(demonstrating the membrane localization of both ER
isoforms and the existence of heterodimers) complement
our in vivo model utilizing the isoform-specific null mice.
Together, they raise an interesting possibility that
ERα/ERβ heterodimers at the membrane may be involved
in modulating eNOS activation and vasodilation. It also
should be noted that no study, to our knowledge, has
proved in vivo that homodimers are sufficient for PI3K
activation. However, details about how the existing
heterodimers in MISS differ functionally from a majority
pool of homodimers remain largely unknown. In order to
isolate the contribution of heterodimers from homodimer
isoforms, we may consider a systematic approach of
mutagenesis, first to define the necessary residues
important for forming heterodimers, and see if they differ
from those needed for homodimerization. Once more
information is known for heterodimer interaction, further
functional studies comparing homodimers and
heterodimers may be possible.
Vasoprotection by E2 is also modulated by nuclear ERs
interacting with co-activators.Transgenic mice lacking
the steroid receptor coactivator-3 (SRC3), a protein highly
expressed in smooth muscle cells and EC, exhibit
pronounced neointimal proliferation. Furthermore, female
mice are less responsive to the inhibitory effect of E2 on
this proliferation [Yuan et al., 2002]. A newly identified
co-repressor of ERα, MRF1 (Modulator Recognition
Factor 1), richly expressed in cardiovascular tissues,
inhibits transcriptional activation by ERα, binds ERβ, and
may be a good candidate to provide modulation of ER
actions on the vasculature [Georgescu et al., 2005].
Another major effect of E2 in the vasculature is the
inhibition of atherosclerosis [Mendelsohn and Karas,
1999]. Proposed mechanisms include anti-inflammatory
actions, reduction of LDL oxidation, and promotion of
re-endothelialization [White, 2002]. Double KO mice
deficient for ERα and apolipoprotein E (Apo-E) indicate
that ERα is a major mediator of the atherosclerosis
reduction [Hodgin et al., 2001]. Apo-E KO mice (ApoE
-/-)
typically develop lipid-induced atherosclerosis and provide
a good experimental model of this disorder. ApoE
-/- mice,
when treated with E2, exhibit 80% less lesions, while
such benefit is abrogated in mice lacking both ERα and
ApoE. By contrast, E2 treatment reduces atherosclerotic
progression equally in ApoE
-/- mice and in ERβ-deficient
ApoE
-/- mice.This finding indicates that the ERα isoform
is the main mediator of atherosclerosis mitigation, and
the underlying mechanism includes upregulation of the
athero-protective prostacyclin, PGI2, by ERα [Egan et
al., 2004].
While ERβ does not appear to alter atherosclerotic
progression significantly, it affects multiple aspects of
vascular integrity in addition to modulating
eNOS-dependent vasodilation [Guo et al., 2005;
Watanabe et al., 2003; Zhu et al., 2002]. For example,
vascular smooth muscle cell proliferation is strongly
inhibited by ERβ [Watanabe et al., 2003]. Furthermore,
deleting this ER subtype in mice results in ion channel
abnormalities of vascular smooth muscle cells, attenuation
of endothelium-independent iNOS production and
subsequent vasoconstriction, and the development of
both systolic and diastolic hypertension [Zhu et al., 2002].
Related to the issue is a possibility that E2/ERs can
mitigate abnormal ventricular hypertrophy of the heart,
commonly resulting from long-standing hypertension.
Effects of estrogen on the myocardium
Left ventricular hypertrophy (LVH) of the heart is an
independent risk factor for adverse cardiovascular
outcomes such as stroke and heart failure [Gosse, 2005].
It has been noted that pre-menopausal women have a
lower prevalence of LVH than age-matched men
[Agabiti-Rosei and Muiesan, 2002], and that hormone
replacement therapy (HRT) with E2 reverses LVH in
postmenopausal women [Miya et al., 2002; Modena et
al., 1999]. Animal studies also support the
anti-hypertrophic actions of E2 [van Eickels et al., 2001].
Complementary mechanistic studies indicate that
attenuation of LVH is not just an indirect sequela of
E2-related afterload reduction. E2 efficiently reduces
angiotensin II (AngII)- or endothelin 1 (ET1)-induced
hypertrophy of individual cardiomyocytes, resulting in a
smaller cell surface area and decreased cytoskeletal
protein expression [Pedram et al., 2005].
Detailed in vitro data suggest that underlying mechanisms
are multifold and entail the following [Pedram et al., 2005].
E2 blocks AngII- or ET1- initiated hypertrophic signaling,
in part through activation of PI3K. A notable downstream
event is upregulation of the gene encoding modulatory
calcineurin-interacting protein (MCIP), a calcineurin
antagonist. E2 stimulates both the transcriptional
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Inhibition of calcineurin phosphatase activity by MCIP
subsequently prevents nuclear translocation of a family
of transcription factors, called nuclear factor of activated
T cells (NF-AT).This prevents NF-AT transcriptional
activity and subsequent stimulation of the cardiac
hypertrophic gene response. In addition, E2 antagonizes
AngII-induced extracellular signal-regulated kinase (ERK)
and protein kinase C (PKC), two modulators central to
hypertrophic signaling [Braz et al., 2002]. Inhibition of
these two kinases by E2/ERs involves the upregulation
of atrial natriuretic peptide (ANP) production and appears
independent of interaction with MCIP. However, crosstalk
between the calcineurin-NFAT pathway and PKC-ERK
signaling exists in cardiomyocytes [Pedram et al., 2005;
Sanna et al., 2005], and may provide the basis for E2/ERs
to achieve the overall antihypertrophic effect at multiple
points of the interrelated pathways.Therefore, E2/ERs
mitigate cardiac hypertrophy in this model via an
integrative fashion involving actions at MISS and
transactivation of the involved genes.We believe that
E2-activated PI3K signaling to MCIP transactivation
provides an example of MISS signaling to transcription
in cardiomyocytes [Pedram et al., 2005].
As observed in both the vascular function and effects on
LVH, association of ERs with PI3K plays an important
protective role in ischemia-reperfusion (I/R) injury to the
heart. I/R injury is strongly linked to cardiomyocyte loss
via apoptosis, probably due to a combination of a
significant ischemic burden and oxidative stress from
reperfusion. In an animal model of myocardial infarction
by permanent coronary occlusion, E2 protection of the
heart includes reducing infarct size and decreased
myocyte apoptosis due to activation of the PI3K/Akt
pathway [Patten et al., 2004]. Similar E2-mediated
signaling may protect cardiomyocytes from I/R-related
injury, including apoptosis. Indeed, a simulated I/R model
in vitro from our laboratory shows that E2-mediated
reduction of cardiomyocyte apoptosis involves activation
of PI3K/Akt [Kim et al., 2006].
In general, there are two types of apoptosis: a
“death-receptor”-driven extrinsic pathway and a
mitochondria-centered intrinsic pathway. It is not
completely known where in the apoptotic signaling E2/ER
intervenes, and data regarding E2 actions on apoptosis
in the heart are still limited. Nevertheless, several known
features of estrogen are relevant to the cytoprotective
mechanism of E2 in the cardiomyocyte. For example, E2
serves as an antioxidant in differentiated cells such as
neurons. Oxidative stress and the subsequent generation
of reactive oxygen species (ROS) following coronary
reperfusion are thought to be a potent trigger for
cardiomyocyte apoptosis [Zhao, 2004].The ability of
E2/ERs to counteract such redox intermediates is likely
to be a key component of the overall protection. In
addition, E2 modulates yet another important kinase
participating in the cell fate upon stress: p38 MAPK. Of
the known p38 isoforms (α, β, δ, and γ), p38α is a
predominant form expressed in the heart, upregulated in
ischemia, and considered to induce apoptosis. On the
other hand, p38β (also found in cardiomyocytes) is often
anti-apoptotic in function. Importantly, E2 modulates the
two isoforms differentially, inhibiting p38α and stimulating
p38β. In vitro data from our laboratory using cultured
cardiomyocytes and simulated I/R suggest that E2
activation of PI3K is linked to ROS suppression and p38β
upregulation.This signaling leads to p38α downregulation
and cell survival [Kim et al., 2006]. By modulating these
key signaling molecules in the apoptotic pathway, E2/ER
efficiently reduces cell death.
Which ER is responsible for cardioprotection from I/R?
The two isoforms have differential intracellular localization
upon ligand activation (ERα is mainly translocated to the
nucleus with some receptors at the plasma membrane,
in contrast to ERβ seen mainly in
mitochondrial/perinuclear areas as well as the membrane
[Pedram et al., 2005;Yang et al., 2004]). In vivo models
of myocardial infarction and heart failure utilizing either
ERα or ERβ knockout mice support the conclusion that
both ERα and ERβ are essential in E2-related protection
of cardiomyocytes from an ischemic insult [Booth et al.,
2005; Gabel et al., 2005; Pelzer et al., 2005; Zhai et al.,
2000].This may result in part from signaling by ERα/β
heterodimers [Li et al., 2004], either in the nucleus or at
the plasma membrane [Guo et al., 2005]. How ERs acting
as heterodimers might intercede in apoptotic signaling is
not clear at this point.
Conclusion
Estrogen acting through ERs confers critical protection
to the cardiovascular system by its pleiotropic effects in
signaling. E2-mediated outcomes include several
important physiological adaptive responses:
anti-atherogenic actions, vasodilation and preservation
of vascular integrity, alleviation of left ventricular
hypertrophy, and cardiomyocyte survival by preventing
apoptosis.
Despite much human and animal experimental data,
doubt was cast regarding the beneficial effects of estrogen
when HRT was tested as a primary intervention for
atherosclerotic heart disease in the Women’s Health
Initiative trial (WHI) [Rossouw et al., 2002]. However, the
conclusions from the trial have been challenged on
several bases [Mendelsohn and Karas, 2005;Turgeon
et al., 2004]. For example, the trial methodology overlooks
the critical relationship between the timing of HRT
initiation and the natural history of atherosclerosis in
women.The study population was post-menopausal at
a mean age of 63, and had more than a decade of
estrogen deficiency at enrollment. Furthermore, the
majority of subjects were obese, predisposing them to
atherosclerotic heart disease during the period of estrogen
deficiency.Thus, many of the women at the initial
screening already had features associated with
atherosclerosis in this trial designed for primary
prevention. In addition, the results derived from the use
of the specific hormone formulation in the trial may not
be applicable to other HRT available. Currently, optimized
clinical trials are under way to clearly define the long-term
effects of early intervention HRT on arteriosclerosis. In
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demonstrating potent beneficial effects of E2 on the heart
and vasculature warrant continued research efforts to
investigate the mechanisms and develop related
therapeutic intervention.
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